Evaluation of Thromboelastometry (ROTEM) During Spinal Surgery

Blood Loss, Surgical Clinical Trial

— ROTEM_SPINE  

Official title:

A Prospective, Randomized, Parallel-group Single Center Study to Evaluate the Use of Thromboelastometry (ROTEM) in Patients Undergoing Spine Surgeries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02740374
• Other study ID #: 2014H0447
• Status: Completed
• Phase: N/A
• Start date: November 2015
• Est. completion date: January 28, 2021

Study information

• Verified date: November 2022
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the use of ROTEM, during spinal surgery is effective on diminishing the total blood loss and the risk of Allogenic Transfusion of Blood Products vs control cases without ROTEM assessment.

Description:

Study methods This is a prospective, randomized parallel-group single center study in patients undergoing elective major spine surgery. Patients will be randomized to ROTEM-guided hemostatic therapy algorithm or standard of care hemostatic therapy: arterial blood gas analysis (ABG), normalized index ratio (INR), prothrombin time (PT), thromboplastin time (aPTT), hemoglobin (Hb), platelets, and fibrinogen. Study Procedures Patients will be randomized in a 1:1 ratio to either standard of care coagulation tests (SOC) or ROTEM. No changes in surgery or anesthesia technique will be made for the purposes of the study. Standard of Care Coagulation Tests If patients are randomized to standard of care coagulation tests, these will be performed according to Ohio State University Wexner Medical Center standard practices and attending's criteria. Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperative at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. ROTEM If patients are randomized to ROTEM, the anesthesiologist will be blinded to any intraoperative conventional coagulation test that might be performed. ROTEM will be used according to the manufacturer's instructions, using equipment and test reagents provided by Tem International GmbH. All tests will be performed at the bedside by a clinical perfusionist trained to perform ROTEM. A specific algorithm has been created and should be followed according to clinical criteria ROTEM monitoring will be performed in patients with signs of clinically relevant diffuse bleeding and in whom blood transfusion is considered (Temp >35 Celsius degrees; pH lower than 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation. Patient´s clinical situation should be consider as the most important component on the transfusion decision-making process. Packed erythrocytes will be transfused to maintain hemoglobin concentrations higher 9g/dl and higher 10g/dl in individuals with underlying cardiovascular disease or anticipated greater blood loss. Individual based dynamics strongly indicating the need for erythrocyte transfusion at anesthesiologist criteria will be also part of the transfusion making decision-making process (tachycardia, hypotension, sings of ischemia on electrocardiogram, lactic acidosis, and dynamics of bleeding). Assessment and reporting of Adverse Events The occurrence of adverse events (AE) and serious adverse events (SAE) will be recorded from the time of consent until discharge. For each AE, the relationship to the study procedures and monitoring, severity, expectedness, outcome will be determined by the PI and recorded in the study source accordingly If the case a subject withdraws from the study due to a serious adverse event the local Institutional Review Board (IRB) will be notified within 10 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: January 28, 2021
• Est. primary completion date: January 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female age 18 years or older.

2. Able to provide inform consent or have a legal authorized representative able to sign consent on the patients behalf.

3. Female subject with a negative urine or serum pregnancy test, or not of childbearing potential, defined as surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy; or are postmenopausal for at least 1 year.

4. Patients schedule to undergo elective neurosurgery, orthopedic, or combined procedures that are expected to receive blood products intraoperatively. -

Exclusion Criteria:

1. Subjects younger than 18 years old.

2. Subjects who are prisoners.

3. Subjects who refuse transfusion of blood products.

4. Females who are pregnant or breastfeeding.

5. Subjects unable to participate in the study for any reason in the opinion of the Principal Investigator.

Related Conditions & MeSH terms

• Blood Loss, Surgical
• Hemorrhage

Intervention

Device:
• ROTEM
ROTEM coagulation assessment and guided transfusion management.

Other:
• Standard of Care
Standard Coagulation Tests assessment and guided transfusion management

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Cost Comparison	Compare costs of ROTEM guided therapy or Standard of Care guided therapy.	within 30 days after surgery
Primary	Number of Participants Needing an Intraoperative Autologue Blood Product Transfusion	Intraoperative Autologue Blood Product Transfusion	Within surgery
Secondary	Postoperative Blood Product Transfusion	Fresh frozen plasma transfusion.	Within postoperative 24 hours
Secondary	Number of Participants Requiring Cryoprecipitate Transfusion	Number of participants	Perioperative- up to 24 hours after surgery start time (cumulative)
Secondary	Number of Participants Requiring Platelet Transfusion	Number of participants	Perioperative- up to 24 hours after surgery start time (cumulative)
Secondary	Fibrinogen Concentrate Transfusion Requirements	Percentage	Within Surgery and Postoperative 24 hours
Secondary	Prothrombin Complex Transfusion Requirements	Percentage	Within Surgery and Postoperative 24 hours
Secondary	Factor VII Transfusion Requirements	Percentage	Within Surgery and Postoperative 24 hours
Secondary	Need for Mechanical Ventilation During Postoperative Period		Within 30 days after surgery
Secondary	Length of Stay on Intensive Care Unit (ICU)		Within 30 days after surgery
Secondary	Length of Stay on Post Anesthesia Care Unit (PACU)		Within 30 days after surgery
Secondary	Overall Hospital Stay		Within 30 days after surgery
Secondary	Surgical Site Infection		within 30 days after surgery
Secondary	Mortality	30 day mortality	within 30 days after surgery
Secondary	Cardiovascular Complications Rate		within Postoperative 30 days
Secondary	Thromboembolic Complications Rate		within Postoperative 30 days
Secondary	Respiratory Complications Rate		Within postoperative 30 days
Secondary	Renal System Complications Rate		Within 30 postoperative days
Secondary	Cerebrovascular Complications Rate		within 30 postoperative days
Secondary	Infectious Complications Rate		Within postoperative 30 days
Secondary	Reintervention Related to Postoperative Bleeding Rate		Within postoperative 30 days